Two Sigma Advisers LP Purchases 11,600 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Two Sigma Advisers LP boosted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 34.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 45,600 shares of the company's stock after acquiring an additional 11,600 shares during the period. Two Sigma Advisers LP owned 0.06% of IDEXX Laboratories worth $18,853,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Geode Capital Management LLC lifted its position in IDEXX Laboratories by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company's stock worth $948,279,000 after acquiring an additional 37,734 shares during the last quarter. Bamco Inc. NY lifted its position in IDEXX Laboratories by 4.3% during the 4th quarter. Bamco Inc. NY now owns 2,005,522 shares of the company's stock worth $829,163,000 after acquiring an additional 82,264 shares during the last quarter. Invesco Ltd. increased its holdings in shares of IDEXX Laboratories by 6.8% during the 4th quarter. Invesco Ltd. now owns 1,160,988 shares of the company's stock worth $479,999,000 after purchasing an additional 74,324 shares during the period. Norges Bank bought a new position in shares of IDEXX Laboratories during the 4th quarter worth about $412,258,000. Finally, Northern Trust Corp increased its holdings in shares of IDEXX Laboratories by 18.6% during the 4th quarter. Northern Trust Corp now owns 912,874 shares of the company's stock worth $377,419,000 after purchasing an additional 143,369 shares during the period. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Trading Up 2.9%

NASDAQ:IDXX traded up $14.52 during trading hours on Tuesday, hitting $516.09. The stock had a trading volume of 148,187 shares, compared to its average volume of 797,331. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $530.60. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The business's 50 day moving average is $442.28 and its 200-day moving average is $435.02. The company has a market cap of $41.50 billion, a price-to-earnings ratio of 48.37, a P/E/G ratio of 3.41 and a beta of 1.52.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The business had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. During the same period last year, the business posted $2.71 earnings per share. The firm's quarterly revenue was up 3.6% on a year-over-year basis. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of IDEXX Laboratories stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the sale, the director now directly owns 1,801 shares in the company, valued at approximately $922,724.34. The trade was a 41.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.98% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Morgan Stanley boosted their price objective on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a report on Monday, May 5th. Barclays upped their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Bank of America upped their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research note on Tuesday, February 4th. Piper Sandler upped their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research note on Monday, February 10th. Finally, Stifel Nicolaus upped their target price on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a research note on Monday, May 19th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $536.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.